NCT00764231

Brief Summary

Fatigue is the most common and disabling symptom in acute myeloid leukaemia (AML). Studies in other cancer patients with fatigue have shown that exercise improves both fatigue and quality of life (QOL), but there are no such studies in AML. The investigators want to conduct a pilot study of a home-based exercise program to see if this type of exercise program is feasible for AML patients, reduces fatigue, and improves QOL. What the investigators learn from this study will be essential to designing a larger, definitive randomized trial of exercise in patients with AML.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Oct 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 1, 2008

Completed
Same day until next milestone

Study Start

First participant enrolled

October 1, 2008

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2011

Completed
Last Updated

February 8, 2012

Status Verified

February 1, 2012

Enrollment Period

2.3 years

First QC Date

September 30, 2008

Last Update Submit

February 7, 2012

Conditions

Keywords

acute myeloid leukemiaexercisefatiguequality of lifehome-basedAML

Outcome Measures

Primary Outcomes (1)

  • Quality of life (fatigue, global health)

    12 weeks

Secondary Outcomes (2)

  • Recruitment rate

    12 weeks

  • Adherence rate

    12 weeks

Study Arms (2)

Exercise

EXPERIMENTAL

This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.

Behavioral: Home-based exercise program

Wait list control

OTHER

This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.

Behavioral: Wait list

Interventions

Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.

Also known as: exercise, fitness
Exercise
Wait listBEHAVIORAL

Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.

Also known as: exercise, fitness
Wait list control

Eligibility Criteria

Age40 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Completion of induction and consolidation chemotherapy
  • AML with histologically confirmed complete remission
  • Fluency in English (or availability of bilingual caregiver and fluency in language for which validated translations of the FACT-Fatigue exist)
  • Potential participants must also be screened with the Physical Activity Readiness Questionnaire (PAR-Q \& PAR-MedX) and receive physician approval to participate in an exercise program

You may not qualify if:

  • Another active malignancy
  • Life expectancy \< 3 months
  • Severe or unstable cardiorespiratory disease
  • Bone marrow transplant candidates

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Princess Margaret Hospital

Toronto, Ontario, M5G 1Z5, Canada

Location

MeSH Terms

Conditions

Leukemia, Myeloid, AcuteMotor ActivityFatigue

Interventions

ExerciseWaiting Lists

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesBehaviorSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaAppointments and SchedulesOrganization and AdministrationHealth Services Administration

Study Officials

  • Shabbir MH Alibhai, MD, MSc

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff Physician and Senior Scientist

Study Record Dates

First Submitted

September 30, 2008

First Posted

October 1, 2008

Study Start

October 1, 2008

Primary Completion

February 1, 2011

Study Completion

April 1, 2011

Last Updated

February 8, 2012

Record last verified: 2012-02

Locations